Effects of Ignatia amara in mouse behavioural models

Background: Ignatia amara (Ignatia), a remedy made from the Strychnos ignatii seeds, is used for anxiety-related symptoms, but consistent evidence of its activity in reproducible experimental models is lacking. An investigation was performed in order to assess on mice, by means of emotional response models, the activity of homeopathic Ignatia dilutions/dynamizations.

Methods: Groups of 8 mice of the CD1 albino strain were treated intraperitoneally for 9 days with 0.3 ml of five centesimal (C) dilutions/dynamizations of Ignatia (4C, 5C, 7C, 9C and 30C). Control mice were treated with the same hydroalcoholic (0.3%) solution used to dilute the medicines. Diazepam (1 mg/kg) was the positive reference drug. Validated test models for locomotion and emotional response, the Open-Field (OF) and the Light–Dark (LD) tests, were employed. Five replications of the same protocol were carried out, in a randomised way using coded drugs/controls.

Results: In the OF the general locomotion of mice was slightly decreased by Ignatia 4C, but not by Ignatia 5C, 7C, 9C and 30C, indicating the absence of unspecific motor impairment or sedation by these dilutions/dynamizations. Ignatia and diazepam seemed to decrease the number of urine spots released in the OF during 10 min, with borderline significance (P=0.083). In the LD the tested medicine showed anxiolytic-like activity (increase of time spent and distance travelled in the lit area), though to a lesser extent than diazepam. The highest and most significant difference with untreated controls (P < 0.01) was observed with the 9C dilution/dynamization. Among the 5 replication experiments, the best drug effects were obtained where the baseline anxiety of mice was higher.

Conclusions: Homeopathic Ignatia dilutions/dynamizations (peak at 9C) modify some emotion-related symptoms in laboratory mice without affecting locomotion.

Keywords

Strychnos Ignatii - Ignatia - Strychnine - Animal models of anxiety - Open-Field test - Light–Dark test - Homeopathic dilutions/dynamizations - Nanopharmacology

• References

• 1 Mathie R.T., Robinson T.W. Outcomes from homeopathic prescribing in medical practice: a prospective, research-targeted, pilot study. Homeopathy 2006; 95: 199-205.
• 2 Thompson E.A., Mathie R.T., Baitson E.S. et al. Towards standard setting for patient-reported outcomes in the NHS homeopathic hospitals. Homeopathy 2008; 97: 114-121.
• 3 Greeson J.M., Rosenzweig S., Halbert S.C., Cantor I.S., Keener M.T., Brainard G.C. Integrative medicine research at an academic medical center: patient characteristics and health-related quality-of-life outcomes. J Altern Complement Med 2008; 14: 763-767.
• 4 Guethlin C., Walach H., Naumann J., Bartsch H.H., Rostock M. Characteristics of cancer patients using homeopathy compared with those in conventional care: a cross-sectional study. Ann Oncol 2010; 21: 1094-1099.
• 5 Witt C.M., Bluth M., Albrecht H., Weisshuhn T.E., Baumgartner S., Willich S.N. The in vitro evidence for an effect of high homeopathic potencies – a systematic review of the literature. Complement Ther Med 2007; 15: 128-138.
• 6 Vickers A.J. Independent replication of pre-clinical research in homeopathy: a systematic review. Forsch Komplementarmed 1999; 6: 311-320.
• 7 Linde K., Jonas W.B., Melchart D., Worku F., Wagner H., Eitel F. Critical review and meta-analysis of serial agitated dilutions in experimental toxicology. Hum Exp Toxicol 1994; 13: 481-492.
• 8 Fisher P. In vitro models for homeopathic high dilutions: the quest for reproducibility. J Altern Complement Med 2006; 12: 357-358.
• 9 Bellavite P., Magnani P., Marzotto M., Conforti A. Assays of homeopathic remedies in rodent behavioural and psychopathological models. Homeopathy 2009; 98: 208-227.
• 10 Conforti A., Bellavite P., Bertani S., Chiarotti F., Menniti-Ippolito F., Raschetti R. Rat models of acute inflammation: a randomized controlled study on the effects of homeopathic remedies. BMC Complement Altern Med 2007; 7: 1.
• 11 Bellavite P., Conforti A., Ortolani R. Immunology and homeopathy. 3. Experimental studies on animal models. Evid Based Complement Alternat Med 2006; 3: 171-186.
• 12 Betti L., Trebbi G., Majewsky V. et al. Use of homeopathic preparations in phytopathological models and in field trials: a critical review. Homeopathy 2009; 98: 244-266.
• 13 Bonamin L.V., Endler P.C. Animal models for studying homeopathy and high dilutions: conceptual critical review. Homeopathy 2010; 99: 37-50.
• 14 Magnani P., Conforti A., Zanolin E., Marzotto M., Bellavite P. Dose–effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice. Psychopharmacology (Berl) 2010; 210: 533-545.
• 15 Bousta D., Soulimani R., Jarmouni I. et al. Neurotropic, immunological and gastric effects of low doses of Atropa belladonna L., Gelsemium sempervirens L. and Poumon histamine in stressed mice. J Ethnopharmacol 2001; 74: 205-215.
• 16 Venard C., Boujedaini N., Mensah-Nyagan A.G., Patte-Mensah C. Comparative analysis of gelsemine and Gelsemium sempervirens activity on neurosteroid allopregnanolone formation in the spinal cord and limbic system. Evid Based Complement Alternat Med 2009 10.1093/ecam/nep083.
• 17 Morton A.L. Principal drugs and their uses. London: Farber and Farber; 1934.
• 18 Bahrke M.S., Yesalis C. Performance-enhancing substances in sport and exercise. Champaign (IL): Human Kinetics; 2002.
• 19 Guillemain J., Huguet F., Binsard A.M., Tetau M., Narcisse G. Action anti-convulsivante expérimentale de diluitions d’Ignatia chez la souris. Ann Homéop Fr 1981; 23: 35-41.
• 20 Boericke W. Materia medica with repertory. Philadelphia: Boericke & Tafel, Inc; 1927.
• 21 Barbancey J. Pratique Homéopathique en psycho-pathologie, Tome II. Paris: Editions Similia; 1987.
• 22 Guermonprez M. Homéopathie, Principles – Clinique – Techniques. Paris: CEDH; 2006.
• 23 Binsard A.M. Étude psycho-pharmacologique de diluitions homéopathiques d’Ignatia. Ann Homéop Fr 1978; 20: 313-321.
• 24 Guillemain J., Rousseau A., Dorfman P., Tetau M. Recherche en psychopharmacologie. Cah Biother 1989; 103: 53-66.
• 25 Venard C., Boujedaini N., Belon P., Mensah-Nyagan A.G., Patte-Mensah C. Regulation of neurosteroid allopregnanolone biosynthesis in the rat spinal cord by glycine and the alkaloidal analogs strychnine and gelsemine. Neuroscience 2008; 153: 154-161.
• 26 Binsard A.M. Étude psycho-pharmacologique d’Ignatia et rapprochement avec un autre polychreste. Ann Homéop Fr 1979; 21: 369-378.
• 27 Belzung C., Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 2001; 125: 141-149.
• 28 Bourin M., Petit-Demouliere B., Dhonnchadha B.N., Hascoet M. Animal models of anxiety in mice. Fundam Clin Pharmacol 2007; 21: 567-574.
• 29 Fahey J.M., Pritchard G.A., Grassi J.M., Pratt J.S., Shader R.I., Greenblatt D.J. Pharmacodynamic and receptor binding changes during chronic lorazepam administration. Pharmacol Biochem Behav 2001; 69: 1-8.
• 30 Ennaceur A., Michalikova S., van R.R., Chazot P.L. Tolerance, sensitization and dependence to diazepam in Balb/c mice exposed to a novel open space anxiety test. Behav Brain Res 2010; 209: 154-164.
• 31 Walsh R.N., Cummins R.A. The Open-Field Test: a critical review. Psychol Bull 1976; 83: 482-504.
• 32 Simon P., Dupuis R., Costentin J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav Brain Res 1994; 61: 59-64.
• 33 Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003; 463: 3-33.
• 34 Hascoet M., Bourin M., Dhonnchadha B.A. The mouse light–dark paradigm: a review. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 141-166.
• 35 Bourin M., Hascoet M. The mouse light/dark box test. Eur J Pharmacol 2003; 463: 55-65.
• 36 Chen S.W., Min L., Li W.J., Kong W.X., Li J.F., Zhang Y.J. The effects of angelica essential oil in three murine tests of anxiety. Pharmacol Biochem Behav 2004; 79: 377-382.
• 37 Young R., Johnson D.N. A fully automated light/dark apparatus useful for comparing anxiolytic agents. Pharmacol Biochem Behav 1991; 40: 739-743.
• 38 Stock-Schroer B., Albrecht H., Betti L. et al. Reporting experiments in homeopathic basic research (REHBaR) – a detailed guideline for authors. Homeopathy 2009; 98: 287-298.
• 39 Carpenter J.S., Neal J.G. Other complementary and alternative medicine modalities: acupuncture, magnets, reflexology, and homeopathy. Am J Med 2005; 118 (Suppl. 12B): 109-117.
• 40 Hubner R., van H.R., Klein P. Effectiveness of the homeopathic preparation Neurexan compared with that of commonly used valerian-based preparations for the treatment of nervousness/restlessness – an observational study. ScientificWorldJournal 2009; 9: 733-745.
• 41 Thompson E.A. Using homoeopathy to offer supportive cancer care, in a National Health Service outpatient setting. Complement Ther Nurs Midwifery 1999; 5: 37-41.
• 42 Bonne O., Shemer Y., Gorali Y., Katz M., Shalev A.Y. A randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. J Clin Psychiatry 2003; 64: 282-287.
• 43 Pilkington K., Kirkwood G., Rampes H., Fisher P., Richardson J. Homeopathy for anxiety and anxiety disorders: a systematic review of the research. Homeopathy 2006; 95: 151-162.
• 44 Coulter M.K., Dean M.E. Homeopathy for attention deficit/hyperactivity disorder or hyperkinetic disorder. Cochrane Database Syst Rev 2007 CD005648.
• 45 Rao M.L., Roy R., Bell I.R., Hoover R. The defining role of structure (including epitaxy) in the plausibility of homeopathy. Homeopathy 2007; 96: 175-182.
• 46 Elia V., Napoli E., Germano R. The ‘Memory of Water’: an almost deciphered enigma. Dissipative structures in extremely dilute aqueous solutions. Homeopathy 2007; 96: 163-169.
• 47 Smith V.M. Paradoxical reactions to diazepam. Gastrointest Endosc 1995; 41: 182-183.
• 48 Bramness J.G., Skurtveit S., Morland J. Flunitrazepam: psychomotor impairment, agitation and paradoxical reactions. Forensic Sci Int 2006; 159: 83-91.
• 49 Mancuso C.E., Tanzi M.G., Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy 2004; 24: 1177-1185.
• 50 Henderson N.D., Turri M.G., DeFries J.C., Flint J. QTL analysis of multiple behavioral measures of anxiety in mice. Behav Genet 2004; 34: 267-293.
• 51 Bellavite P. Complexity science and homeopathy. A synthetic overview. Homeopathy 2003; 92: 203-212.
• 52 Overall K.L., Dunham A.E. Homeopathy and the curse of the scientific method. Vet J 2009; 180: 141-148.
• 53 Bellavite P., Ortolani R., Pontarollo F., Pitari G., Conforti A. Immunology and homeopathy. 5. The rationale of the ‘Simile’. Evid Based Complement Alternat Med 2007; 4 (02) 149-163.
• 54 Fernandes G.A. Immunological stress in rats induces bodily alterations in saline-treated conspecifics. Physiol Behav 2000; 69 (03) 221-230.
• 55 Guillemain J., Huguet F., Segouin C., Bakri Logeais F., Tetau M., Narcisse G. Liaisons in-vitro de diluitions d’Ignatia et Strychninum aux récepteurs glycinergiques: recherche de spécificité. Ann Homéop Fr 1981; 23: 25-33.
• 56 Calabrese E.J., Jonas W.B. Homeopathy: clarifying its relationship to hormesis. Hum Exp Toxicol 2010; 29: 531-536.
• 57 Bellavite P., Chirumbolo S., Marzotto M. Hormesis and its relationship with homeopathy. Hum Exp Toxicol 2010; 16: 11-18.
• 58 Mattson M.P. Awareness of hormesis will enhance future research in basic and applied neuroscience. Crit Rev Toxicol 2008; 38: 633-639.